“Despite the high prevalence of cardiovascular disease—responsible for a third of deaths globally and nearly a quarter in Australia—early symptoms are often missed,” Sharath Sriram said.
A lightweight, gel-free and waterproof heart monitor is undergoing clinical trials at Midlands Medical Specialists in Perth, Western Australia. Developed by Australian startup Lubdub from RMIT University research, the wearable wireless patch continuously tracks heart rhythms for up to 14 days. The prototype matches the detailed output of a medical-grade electrocardiogram Holter monitor while allowing patients to maintain their normal daily routines.
Cardiovascular disease accounts for nearly a quarter of all deaths in Australia and one-third globally, according to Sriram, an RMIT professor and Lubdub co-founder. Unplanned emergency room admissions often follow years of missed early symptoms, prompting the startup to focus on more accessible outpatient screening.
The Heart Foundation named Lubdub among its 10 most promising heart health projects for 2026. In September, the company closed an oversubscribed $6 million seed funding round, doubling its $3 million target with backing mainly from physicians and heart specialists.
Trial patients wear patch alongside Holter monitors
Patients prescribed a standard Holter monitor wear the new patch during the trial at the Perth clinic. The testing gathers evidence to support further product development and eventual regulatory approval.
“The flexible sensors make better contact with the skin than those used in traditional Holter monitors,” Sriram said.
The design yields data 18 times cleaner than traditional Holter monitors, according to Sriram. That clarity reduces the time required to generate cardiac reports. The technology could allow existing medical workforces to monitor up to 85% more patients before implementing additional tools like artificial intelligence.

Earlier trials involving healthy volunteers established that the patch is comfortable to wear and produces reliable diagnostic data. The current clinic study expands on those initial findings.
Diagnostic Integration Plans
Lubdub plans to combine three separate heart-monitoring technologies into a single software platform. The ECG patch represents the first component of that roadmap.
Future iterations aim to integrate non-invasive cardiac biomarker testing and wearable ultrasound imaging. Accessing these diagnostic tests often requires separate appointments, specialists, and facilities.
For co-founder and director Nikhilesh Bappoo, the fragmentation of cardiac care is a personal issue. A few years ago, Bappoo’s father suffered a heart attack in Perth and received prompt specialist care.
“Had it happened there, the outcome could have been very different,” Bappoo said, reflecting on the limited specialist healthcare infrastructure in Mauritius, where he grew up.
RMIT University licenses intellectual property to Lubdub
Lubdub developed the patch through an ongoing partnership with RMIT University, which included research grants, contracts, and access to pilot manufacturing facilities at Discovery to Device. RMIT recently licensed the intellectual property for both the ECG and biomarker inventions to the startup.
“Lubdub is focused on making a real difference to heart health through cutting-edge electronics invented right here at RMIT,” said Calum Drummond AO, RMIT’s Deputy Vice-Chancellor Research and Innovation.
The university continues to work alongside the company as leadership advances the technology toward regulatory approval and broader clinical use.
Answers to questions about the Lubdub ECG patch trial
Where is the Lubdub ECG patch currently being tested?
The prototype patch is being trialed at Midlands Medical Specialists in Perth, Western Australia, on patients prescribed a traditional Holter monitor.
How long can patients wear the wireless patch continuously?
The device tracks heart rhythms continuously for up to 14 days while patients go about their daily activities.
Flexible sensors make better contact with the skin than traditional Holter monitor leads, producing data that is 18 times cleaner according to RMIT Professor Sharath Sriram.
The startup aims to integrate wearable ECG monitoring, non-invasive cardiac biomarker testing, and wearable ultrasound imaging into a single software platform.
How much funding has Lubdub raised so far?
In September, the company announced an oversubscribed $6 million seed funding round, doubling its original $3 million target with backing mainly from physicians and heart specialists.
Related reading